You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
|
|---|---|
| Published in |
Journal of Translational Medicine, May 2015
|
| DOI | 10.1186/s12967-015-0501-5 |
| Pubmed ID | |
| Authors |
Riccardo Giampieri, Alessandra Mandolesi, Khaled M Abouelkhair, Cristian Loretelli, Michela Del Prete, Luca Faloppi, Bianconi Maristella, Ezzeldin M Ibrahim, Marina Scarpelli, Stefano Cascinu, Mario Scartozzi |
| Abstract |
The aim of our study was to evaluate whether a panel of biomarkers, prospectively analysed might be able to predict patients' clinical outcome more accurately than RAS status alone. K-RAS (exons 2, 3, 4) wild type colorectal cancer patients, candidates to second/third-line cetuximab with chemotherapy were prospectively allocated into 2 groups on the basis of their profile: favourable (BRAF and PIK3CA exon 20 wild type, EGFR GCN ≥ 2.6, HER-3 Rajkumar score ≤ 8, IGF-1 immunostaining < 2) or unfavourable (any of the previous markers altered or mutated). After the introduction of N-RAS status (exons 2, 3, 4) only RAS wild type patients were considered eligible. Primary aim was response rate (RR). To detect a difference in terms of RR among patients with an unfavourable profile (estimated around 25%) and patients with a favourable profile (estimated around 60%), with a probability alpha of 0.05 and beta of 0.05, required sample size was 46 patients. Secondary endpoints were progression free survival (PFS) and overall survival (OS). Forty-six patients were enrolled. Seventeen patients (37%) were allocated to the favourable and 29 patients (63%) to the unfavourable profile. RR in the favourable and unfavourable group was 11/17 (65%) and 2/29 (7%) (p = 0.007) respectively. The favourable group also showed an improved PFS (8 months vs. 3 months, p < 0.0001) and OS (15 months vs. 6 months, p < 0.0001). Our results suggest that prospective selection of optimal candidates for cetuximab treatment is feasible and may be able to improve clinical outcome. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 14% |
| Other | 4 | 14% |
| Student > Ph. D. Student | 3 | 11% |
| Student > Master | 3 | 11% |
| Lecturer | 2 | 7% |
| Other | 6 | 21% |
| Unknown | 6 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 39% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 11% |
| Biochemistry, Genetics and Molecular Biology | 3 | 11% |
| Agricultural and Biological Sciences | 2 | 7% |
| Sports and Recreations | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 7 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 May 2015.
All research outputs
#15,331,767
of 22,803,211 outputs
Outputs from Journal of Translational Medicine
#2,233
of 3,991 outputs
Outputs of similar age
#156,909
of 264,554 outputs
Outputs of similar age from Journal of Translational Medicine
#60
of 91 outputs
Altmetric has tracked 22,803,211 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,991 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,554 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 91 others from the same source and published within six weeks on either side of this one. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.